4.7 Article

Days-Out-of-Role Associated With Insomnia and Comorbid Conditions in the America Insomnia Survey

Journal

BIOLOGICAL PSYCHIATRY
Volume 70, Issue 11, Pages 1063-1073

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.biopsych.2011.08.010

Keywords

Comorbidity; days out of role; epidemiology; insomnia; perceived health; role disability

Funding

  1. Sanofi-Aventis (SA)
  2. Merck
  3. Actelion
  4. Affectis
  5. Astra-Zeneca
  6. BrainLab
  7. Daimler Benz
  8. Daimler Benz, Essex
  9. Daimler Benz, Essex, GlaxoSmithKline
  10. Lundbeck
  11. Neurim
  12. NeuroBiotec
  13. Neurocrine
  14. Novartis
  15. Organon, SA
  16. Schwarz
  17. Schwarz, Sepracor
  18. Takeda
  19. UCB
  20. Volkswagen
  21. Weinmann
  22. Weinmann, and Wyeth
  23. Aventis
  24. Cephalon
  25. Glaxo Smith Kline
  26. Pfizer
  27. Sanofi
  28. SchoeringPlough
  29. Sepracor
  30. Somaxon
  31. Somnus
  32. Syrex
  33. TransOral
  34. Ventus
  35. Wyeth
  36. Xenoport
  37. Vanda
  38. Neurogen, SA
  39. Respironics
  40. Jazz Pharmaceuticals
  41. Analysis Group
  42. Bristol-Myers Squibb
  43. Eli Lilly and Company
  44. EPI-Q
  45. GlaxoSmithKline
  46. Johnson and Johnson Pharmaceuticals
  47. Ortho-McNeil Janssen Scientific Affairs
  48. SA Groupe
  49. Shire US

Ask authors/readers for more resources

Background: Insomnia is highly prevalent and impairing but also highly comorbid with other chronic physical/mental disorders. Population-based research has yet to differentiate the role impairments uniquely associated with insomnia per se from those due to comorbidity. Methods: A representative sample of 6791 adult subscribers to a large national US commercial health plan was surveyed by telephone about sleep and health. Twenty-one conditions previously found to be comorbid with insomnia were assessed with medical/pharmacy claims data and validated self-report scales. The Brief Insomnia Questionnaire, a fully structured, clinically validated scale, generated insomnia diagnoses according to inclusion criteria of DSM-IV-TR, ICD-10, and Research Diagnostic Criteria/International Classification of Sleep Disorders: Diagnostic and Coding Manual, Second Edition. The World Health Organization Disability Assessment Schedule-II assessed number of days in the past 30 when health problems prevented respondents from conducting their usual daily activities. Regression analyses estimated associations of insomnia with days-out-of-role controlling comorbidity. Results: Insomnia was significantly associated with days-out-of-role (.90 days/month) in a gross model. The association was reduced when controls were introduced for comorbidity (.42 days/month). This net association did not vary with number or type of comorbid conditions but was confined to respondents 35 + years of age. Insomnia was one of the most important conditions studied not only at the individual level, where it was associated with among the largest mean days-out-of-role, but also at the aggregate level, where it was associated with 13.6% of all days-out-of-role. Conclusions: Insomnia has a strong net association with days-out-of-role that does not vary as a function of comorbidity.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available